Symptoms of Huntington's disease appear late in life. Research reveals how DNA repeats grow toxic over time, explaining the ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into Phase I trials, with additional preclinical assets targeting Parkinson’s and ...

STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company").

The startup says its specially constructed RNAi therapies can get deep into brain tissue, yielding new ways to treat neurological conditions like Huntington’s.

Harness Therapeutics, a Cambridge biotech unlocking previously undruggable targets to transform the treatment of ...

Flex Ltd. (NASDAQ:FLEX – Get Free Report) was the target of some unusual options trading on Monday. Stock traders purchased 2,443 put options on the company. This is an increase of 71% compared to the ...

Police are investigating a spate of thefts from vehicles on a new-build housing estate in Chester. The thefts occurred ...

This study presents a valuable finding on the alterations in the autophagic-lysosomal pathway in a Huntington's disease model. The evidence supporting the claims of the authors is solid. However, the ...

Argus raised the firm’s price target on Huntington Bancshares (HBAN) to $19 from $17 and keeps a Buy rating on the shares following the Q4 ...

In the fast-paced world of investing, staying ahead requires good ideas and timely decisions. This article highlights five ...

The HDBuzz team caught up with editor emeritus and Huntington's disease specialist, Prof Ed Wild to hear his thoughts on what ...

Huntington Bancshares Inc (HBAN) stock saw a modest uptick, ending the day at $17.2 which represents a slight increase of $0.30 or 1.78% from the prior close of $16.9. The stock opened at $16.87 and ...